SAN DIEGO, Nov. 29, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (FATE) (“Fate Therapeutics” or the “Company”), a clinical-stage biopharmaceutical company dedicated to bringing first-in-class ...
DUBLIN--(BUSINESS WIRE)--The "Induced Pluripotent Stem Cell (iPSC) Industry Report - Market Size, Trends, & Forecasts, 2025" report has been added to ResearchAndMarkets.com's offering. Since the ...
CAMBRIDGE, Mass. & ATLANTA & SEOUL, South Korea--(BUSINESS WIRE)--Cellino, a biotechnology company pioneering autonomous biomanufacturing for personalized regenerative medicine, today announced its ...
4d
Fate Therapeutics Expands Leadership Team with Appointment of Kamal Adawi as Chief Financial Officer
Fate Therapeutics, Inc. (NASDAQ: FATE) (the Company), a clinical-stage biopharmaceutical company dedicated to bringing a pipeline of induced pluripotent stem cell (iPSC)-derived off-the-shelf cellular ...
BEACHWOOD, Ohio, Aug. 5, 2025 /PRNewswire/ -- Trailhead Biosystems, Inc. (TrailBio.com), a biotechnology company advancing scalable human cell models derived from induced pluripotent stem cells (iPSCs ...
In a landmark continuing collaboration, Answer ALS and Cedars-Sinai have announced the completed availability of the largest amyotrophic lateral sclerosis (ALS) patient-based induced pluripotent stem ...
In Alzheimer’s and other diseases with complex genetics, differentiating a single induced pluripotent stem cell (iPSC) line from a single endpoint cell may improperly represent the underlying ...
Taiwan’s biotech industry is living its golden days, and LumiSTAR is certainly one of its shining examples. It all started at Oxford University, when LumiSTAR co-founders Yu-Fen Chang, CEO, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback